BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 34670806)

  • 1. Lung cancer is also a hereditary disease.
    Benusiglio PR; Fallet V; Sanchis-Borja M; Coulet F; Cadranel J
    Eur Respir Rev; 2021 Dec; 30(162):. PubMed ID: 34670806
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Breast cancer patients suggestive of Li-Fraumeni syndrome: mutational spectrum, candidate genes, and unexplained heredity.
    Penkert J; Schmidt G; Hofmann W; Schubert S; Schieck M; Auber B; Ripperger T; Hackmann K; Sturm M; Prokisch H; Hille-Betz U; Mark D; Illig T; Schlegelberger B; Steinemann D
    Breast Cancer Res; 2018 Aug; 20(1):87. PubMed ID: 30086788
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of the Li-Fraumeni Spectrum Based on an International Germline TP53 Variant Data Set: An International Agency for Research on Cancer TP53 Database Analysis.
    Kratz CP; Freycon C; Maxwell KN; Nichols KE; Schiffman JD; Evans DG; Achatz MI; Savage SA; Weitzel JN; Garber JE; Hainaut P; Malkin D
    JAMA Oncol; 2021 Dec; 7(12):1800-1805. PubMed ID: 34709361
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current review of TP53 pathogenic germline variants in breast cancer patients outside Li-Fraumeni syndrome.
    Fortuno C; James PA; Spurdle AB
    Hum Mutat; 2018 Dec; 39(12):1764-1773. PubMed ID: 30240537
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparable frequency of BRCA1, BRCA2 and TP53 germline mutations in a multi-ethnic Asian cohort suggests TP53 screening should be offered together with BRCA1/2 screening to early-onset breast cancer patients.
    Lee DS; Yoon SY; Looi LM; Kang P; Kang IN; Sivanandan K; Ariffin H; Thong MK; Chin KF; Mohd Taib NA; Yip CH; Teo SH
    Breast Cancer Res; 2012 Apr; 14(2):R66. PubMed ID: 22507745
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High Prevalence of Somatic Oncogenic Driver Alterations in Patients With NSCLC and Li-Fraumeni Syndrome.
    Mezquita L; Jové M; Nadal E; Kfoury M; Morán T; Ricordel C; Dhooge M; Tlemsani C; Léna H; Teulé A; Álvarez JV; Raimbourg J; Hiret S; Lacroix L; Menéndez M; Saldaña J; Brunet J; Lianes P; Coupier I; Auclin E; Recondo G; Friboulet L; Adam J; Green E; Planchard D; Frébourg T; Capellà G; Rouleau E; Lázaro C; Caron O; Besse B
    J Thorac Oncol; 2020 Jul; 15(7):1232-1239. PubMed ID: 32179180
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of TP53 pathogenic variants in early-onset HER2-positive breast cancer.
    Escudeiro C; Pinto C; Vieira J; Peixoto A; Pinto P; Pinheiro M; Santos C; Guerra J; Lisboa S; Santos R; Silva J; Leal C; Coimbra N; Lopes P; Ferreira M; Sousa AB; Teixeira MR
    Fam Cancer; 2021 Jul; 20(3):173-180. PubMed ID: 33051812
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hereditary lung cancer syndrome targets never smokers with germline EGFR gene T790M mutations.
    Gazdar A; Robinson L; Oliver D; Xing C; Travis WD; Soh J; Toyooka S; Watumull L; Xie Y; Kernstine K; Schiller JH
    J Thorac Oncol; 2014 Apr; 9(4):456-63. PubMed ID: 24736066
    [TBL] [Abstract][Full Text] [Related]  

  • 9.
    da Silva PFF; Goveia RM; Teixeira TB; Gamba BF; de Lima AP; Rogatto SR; Silveira-Lacerda EP
    Biomolecules; 2022 Apr; 12(5):. PubMed ID: 35625568
    [No Abstract]   [Full Text] [Related]  

  • 10. TP53 germline mutation testing in 180 families suspected of Li-Fraumeni syndrome: mutation detection rate and relative frequency of cancers in different familial phenotypes.
    Ruijs MW; Verhoef S; Rookus MA; Pruntel R; van der Hout AH; Hogervorst FB; Kluijt I; Sijmons RH; Aalfs CM; Wagner A; Ausems MG; Hoogerbrugge N; van Asperen CJ; Gomez Garcia EB; Meijers-Heijboer H; Ten Kate LP; Menko FH; van 't Veer LJ
    J Med Genet; 2010 Jun; 47(6):421-8. PubMed ID: 20522432
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characteristics of TP53 germline variants and their correlations with Li-Fraumeni syndrome or Li-Fraumeni-like syndrome in Chinese tumor patients.
    Tian P; Zhang X; Yang S; Fang Y; Yuan H; Li W; Zhu H; Zhao F; Ding J; Zhu Y; Wang S; Sun G; Ni H; Ma T; Lei T
    J Genet Genomics; 2022 Jul; 49(7):645-653. PubMed ID: 35033608
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biochemical and imaging surveillance in germline TP53 mutation carriers with Li-Fraumeni syndrome: 11 year follow-up of a prospective observational study.
    Villani A; Shore A; Wasserman JD; Stephens D; Kim RH; Druker H; Gallinger B; Naumer A; Kohlmann W; Novokmet A; Tabori U; Tijerin M; Greer ML; Finlay JL; Schiffman JD; Malkin D
    Lancet Oncol; 2016 Sep; 17(9):1295-305. PubMed ID: 27501770
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Germline
    Oxnard GR; Chen R; Pharr JC; Koeller DR; Bertram AA; Dahlberg SE; Rainville I; Shane-Carson K; Taylor KA; Sable-Hunt A; Sholl LM; Teerlink CC; Thomas A; Cannon-Albright LA; Fay AP; Ashton-Prolla P; Yang H; Salvatore MM; Addario BJ; Jänne PA; Carbone DP; Wiesner GL; Garber JE
    J Clin Oncol; 2023 Dec; 41(34):5274-5284. PubMed ID: 37579253
    [TBL] [Abstract][Full Text] [Related]  

  • 14. p53 major hotspot variants are associated with poorer prognostic features in hereditary cancer patients.
    Fortuno C; Pesaran T; Dolinsky J; Yussuf A; McGoldrick K; Kho PF; James PA; Spurdle AB
    Cancer Genet; 2019 Jun; 235-236():21-27. PubMed ID: 31296311
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Li-Fraumeni and Li-Fraumeni-like syndrome among children diagnosed with pediatric cancer in Southern Brazil.
    Giacomazzi J; Selistre SG; Rossi C; Alemar B; Santos-Silva P; Pereira FS; Netto CB; Cossio SL; Roth DE; Brunetto AL; Zagonel-Oliveira M; Martel-Planche G; Goldim JR; Hainaut P; Camey SA; Ashton-Prolla P
    Cancer; 2013 Dec; 119(24):4341-9. PubMed ID: 24122735
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risks of first and subsequent cancers among TP53 mutation carriers in the National Cancer Institute Li-Fraumeni syndrome cohort.
    Mai PL; Best AF; Peters JA; DeCastro RM; Khincha PP; Loud JT; Bremer RC; Rosenberg PS; Savage SA
    Cancer; 2016 Dec; 122(23):3673-3681. PubMed ID: 27496084
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Germline TP53 Mutations in Patients With Early-Onset Colorectal Cancer in the Colon Cancer Family Registry.
    Yurgelun MB; Masciari S; Joshi VA; Mercado RC; Lindor NM; Gallinger S; Hopper JL; Jenkins MA; Buchanan DD; Newcomb PA; Potter JD; Haile RW; Kucherlapati R; Syngal S;
    JAMA Oncol; 2015 May; 1(2):214-21. PubMed ID: 26086041
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Revisiting tumor patterns and penetrance in germline TP53 mutation carriers: temporal phases of Li-Fraumeni syndrome.
    Amadou A; Achatz MIW; Hainaut P
    Curr Opin Oncol; 2018 Jan; 30(1):23-29. PubMed ID: 29076966
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Whole body magnetic resonance imaging (WB-MRI) and brain MRI baseline surveillance in TP53 germline mutation carriers: experience from the Li-Fraumeni Syndrome Education and Early Detection (LEAD) clinic.
    Bojadzieva J; Amini B; Day SF; Jackson TL; Thomas PS; Willis BJ; Throckmorton WR; Daw NC; Bevers TB; Strong LC
    Fam Cancer; 2018 Apr; 17(2):287-294. PubMed ID: 28988289
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    Terradas M; Mur P; Belhadj S; Woodward ER; Burghel GJ; Munoz-Torres PM; Quintana I; Navarro M; Brunet J; Lazaro C; Pineda M; Moreno V; Capella G; Evans DGR; Valle L
    Gut; 2021 Jun; 70(6):1139-1146. PubMed ID: 32998877
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.